Prolonged Remission in Neuromyelitis Optica Following Cessation of Rituximab Treatment

Academic Article

Abstract

  • © SAGE Publications. Neuromyelitis optica is an autoimmune disease characterized by acute episodes of transverse myelitis and optic neuritis. Several small, open-label studies suggest rituximab, a monoclonal antibody against CD20, prevents relapses in neuromyelitis optica; however, there is little consensus on timing or duration of treatment. Here we report four patients with severe relapsing neuromyelitis optica who were stabilized on rituximab and, after discontinuing treatment, continued to experience prolonged remission of their disease. Remission ranged from 4.5 to 10.5 years total, including 3 to 9 years off all therapies. The patients had sustained clinical responses despite normal B-lymphocyte levels and, in at least 2 patients, continued seropositivity for aquaporin-4 antibodies. These cases suggest that rituximab may induce prolonged remission in certain neuromyelitis optica patients, and they highlight the need for further elucidation of rituximabs mechanism in neuromyelitis optica.
  • Authors

    Published In

    Digital Object Identifier (doi)

    Pubmed Id

  • 26943898
  • Author List

  • Weinfurtner K; Graves J; Ness J; Krupp L; Milazzo M; Waubant E
  • Start Page

  • 1366
  • End Page

  • 1370
  • Volume

  • 30
  • Issue

  • 10